source
- Novartis stops ALS TREM2 stabilizer after Phase 2 miss, marking fourth trial setback in a monthNovartis has halted development of its TREM2 stabilizer VHB937, also known as lifonebart, for amyotrophic lateral sclerosis after the drug failed to meet either the primary or secondary endpoints i…
- 'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrandNovo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to chief rival Eli Lilly—isn’t one to make changes for the sake of change.